Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina A Antoniu

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Expert Opinion on Biological Therapy|August 11, 2010
GM-CSF pathway correction in pulmonary alveolar proteinosisSabina A Antoniu
Recent Patents on Inflammation & Allergy Drug Discovery|September 1, 2010
Daclizumab: a potential asthma therapy?Sabina A Antoniu
Expert Opinion on Investigational Drugs|August 19, 2006
Rituximab for refractory Wegener's granulomatosisSabina A Antoniu
Expert Opinion on Investigational Drugs|January 26, 2006
Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?Sabina A Antoniu
Expert Opinion on Investigational Drugs|October 27, 2009
Discontinued drugs 2008: pulmonary and allergySabina A Antoniu
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2009
Reducing mortality for chronic obstructive pulmonary disease: role of statins and angiotensin-converting enzyme inhibitorsSabina A Antoniu
Expert Opinion on Therapeutic Targets|May 19, 2006
Targeting tumour necrosis factor-alpha in corticosteroid-dependent asthmaSabina A Antoniu
Expert Opinion on Pharmacotherapy|May 31, 2006
Daily versus intermittent corticosteroids for the treatment of mild persistent asthmaSabina A Antoniu
Expert Opinion on Investigational Drugs|February 17, 2007
Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666Sabina A Antoniu
Expert Review of Pharmacoeconomics & Outcomes Research|April 14, 2010
Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary diseaseSabina A Antoniu
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Expert Opinion on Biological Therapy|August 11, 2010
GM-CSF pathway correction in pulmonary alveolar proteinosisSabina A Antoniu
Recent Patents on Inflammation & Allergy Drug Discovery|September 1, 2010
Daclizumab: a potential asthma therapy?Sabina A Antoniu
Expert Opinion on Investigational Drugs|August 19, 2006
Rituximab for refractory Wegener's granulomatosisSabina A Antoniu
Expert Opinion on Investigational Drugs|January 26, 2006
Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?Sabina A Antoniu
Expert Opinion on Investigational Drugs|October 27, 2009
Discontinued drugs 2008: pulmonary and allergySabina A Antoniu
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2009
Reducing mortality for chronic obstructive pulmonary disease: role of statins and angiotensin-converting enzyme inhibitorsSabina A Antoniu
Expert Opinion on Therapeutic Targets|May 19, 2006
Targeting tumour necrosis factor-alpha in corticosteroid-dependent asthmaSabina A Antoniu
Expert Opinion on Pharmacotherapy|May 31, 2006
Daily versus intermittent corticosteroids for the treatment of mild persistent asthmaSabina A Antoniu
Expert Opinion on Investigational Drugs|February 17, 2007
Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666Sabina A Antoniu
Expert Review of Pharmacoeconomics & Outcomes Research|April 14, 2010
Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary diseaseSabina A Antoniu
Pageof 7